As some studies have discovered various FGFR mutations in up to 60% of all urothelial carcinoma and FGFR3 mutations in 15% of metastatic urothelial carcinoma, new bladder cancer therapies have begun targeting patients with FGFR‐specific mutations.8 Here, FGFR3 is linked to urinary bladder cancer.